Лекарственная терапия метастатического рака желудка

Лекарственная терапия метастатического рака желудка

Автор: Кузнецова О.А., Федянин М.Ю., Найдин Г.М., Бесова Н.С., Трякин А.А.

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 3S1 т.12, 2022 года.

Бесплатный доступ

Рак желудка представляет собой одну из наиболее распространенных причин смерти от рака во всем мире. В случае распространенного и нерезектабельного заболевания ведущим методом лечения является системная терапия. Подходы к выбору оптимальной тактики лекарственного лечения пациентов с диагнозом аденокарцинома желудка претерпели изменения в последние годы. Появление новых молекул и предиктивных биомаркеров делает алгоритм принятия решений более сложным. В статье представлен обзор литературы, освещающей особенности выбора терапии в тактике ведения пациентов с распространенным раком желудка.

Аденокарцинома желудка, лекарственная терапия

Короткий адрес: https://sciup.org/140295812

IDR: 140295812   |   DOI: 10.18027/2224-5057-2022-12-3s1-17-26

Список литературы Лекарственная терапия метастатического рака желудка

  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 ; 71 (3) : 209-249. https://doi.org/10.3322/caac.21660.
  • SEER Cancer Statistics https://seer.cancer.gov/statfacts/html/stomach.html.
  • Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 ; 8 (2) : 163-168. https://doi.org/10.1023/a:1008243606668.
  • Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 ; 71 (3) : 587-591. https://doi.org/10.1038/bjc.1995.114.
  • Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017 ; 8 (8) : CD004064. Published 2017 Aug 29. https://doi.org/10.1002/14651858.CD004064.pub4.
  • Smyth EC, Verheij M, Allum W, et al. Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 ; 27 (suppl 5) : v38-v49. https://doi.org/10.1093/annonc/mdw350.
  • Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer : a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019 ; 30 (1) : 19-33. https://doi.org/10.1093/annonc/mdy502.
  • Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer : a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 ; 24 (18) : 2903- 2909. https://doi.org/10.1200/JCO.2005.05.0245.
  • Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 ; 21 (8) : 1045-1056. https://doi.org/10.1016/S1470-2045(20)30315-6.
  • Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer : a systematic review and meta-analysis. Gastric Cancer. 2011 ; 14 (1) : 50-55. https://doi.org/10.1007/s10120-011-0007-7.
  • Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 ; 358 (1) : 36-46. https://doi.org/10.1056/NEJMoa073149.
  • Ryu MH, Kang YK. ML17032 trial : capecitabine / cisplatin versus 5-fluorouracil / cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2009 ; 9 (12) : 1745-1751. https://doi.org/10.1586/era.09.149.
  • Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials : evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009 ; 20 (9) : 1529- 1534. https://doi.org/10.1093/annonc/mdp047.
  • Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma : a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study [published correction appears in J Clin Oncol. 2015 Apr 20 ; 33 (12) : 1416]. J Clin Oncol. 2014 ; 32 (31) : 3520-3526. https://doi.org/10.1200/JCO.2013.54.1011.
  • Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group. J Clin Oncol. 2006 ; 24 (31) : 4991-4997. https://doi.org/10.1200/JCO.2006.06.8429.
  • Shah MA, Janjigian YY, Stoller R, et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma : A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015 ; 33 (33) : 3874-3879. https://doi.org/10.1200/JCO.2015.60.7465.
  • Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer : a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65 +). Eur J Cancer. 2013 ; 49 (4) : 835-842. https://doi.org/10.1016/j.ejca.2012.09.025.
  • Park H, Jin RU, Wang-Gillam A, et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers : A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 ; 6 (8) : 1231- 1240. https://doi.org/10.1001/jamaoncol.2020.2020.
  • Guo X, Zhao F, Ma X, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer : a systematic review and meta-analysis. BMC Cancer. 2019 ; 19 (1) : 1125. Published 2019 Nov 20. https://doi.org/10.1186/s12885-019-6294-9.
  • Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013) : an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 ; 4 (7) : 501-510. https://doi.org/10.1016/S2468-1253(19)30083-4.
  • Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 ; 29 (30) : 3968- 3976. https://doi.org/10.1200/JCO.2011.36.2236.
  • Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3) : a randomised, open-label phase 3 trial [published correction appears in Lancet Oncol. 2013 Jun ; 14 (7) : e254. Frances, Alicia [corrected to Okines, Alicia Frances Clare]]. Lancet Oncol. 2013 ; 14 (6) : 481-489. https://doi.org/10.1016/S14702045(13)70096-2.
  • Shah MA, Bang YJ, Lordick F, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma : The METGastric Randomized Clinical Trial. JAMA Oncol. 2017 ; 3 (5) : 620-627. https://doi.org/10.1001/jamaoncol.2016.5580.
  • Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 ; 18 (11) : 1467-1482. https://doi.org/10.1016/S1470-2045(17)30566-1.
  • Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL) : a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2019 May ; 20 (5) : e242]. Lancet Oncol. 2019 ; 20 (3) : 420-435. https://doi.org/10.1016/S1470-2045(18)30791-5.
  • Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA) : a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct 16 ; 376 (9749) : 1302]. Lancet. 2010 ; 376 (9742) : 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X.
  • O’Hare, A. Highlights from the latest news and research in clinical investigation. Clin. Investig. (Lond). 2, 761-763 (2012).
  • Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB) : final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018 ; 19 (10) : 1372-1384. https://doi.org/10.1016/S1470-2045(18)30481-9.
  • Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013 ; 49 (6) : 1448-1457. https://doi.org/10.1016/j.ejca.2012.10.018.
  • Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma : issues related to heterogeneity in biopsies and resections. Histopathology. 2011 ; 59 (5) : 832-840. https://doi.org/10.1111/j.1365-2559.2011.04017.x.
  • Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010 ; 457 (3) : 299-307. https://doi.org/10.1007/s00428-010-0952-2.
  • Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer : results from a validation study. Histopathology. 2008 ; 52 (7) : 797-805. https://doi.org/10.1111/j.13652559.2008.03028.x.
  • Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma : Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 ; 140 (12) : 1345-1363. https://doi.org/10.5858/arpa.2016-0331-CP.
  • Viúdez A, Carmona-Bayonas A, Gallego J, et al. Optimal duration of first-line chemotherapy for advanced gastric cancer : data from the AGAMENON registry. Clin Transl Oncol. 2020 ; 22 (5) : 734-750. https://doi.org/10.1007/s12094-019-02183-y.
  • Fanotto V, Cordio S, Pasquini G, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2017 ; 20 (5) : 825-833. https://doi.org/10.1007/s10120-016-0681-6.
  • Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer : who may benefit?. Br J Cancer. 2008 ; 99 (9) : 1402-1407. https://doi.org/10.1038/sj.bjc.6604732.
  • Kanagavel D, Pokataev IA, Fedyanin MY, et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010 ; 21 (9) : 1779-1785. https://doi.org/10.1093/annonc/mdq032.
  • Fuchs CS, Muro K, Tomasek J, et al. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017 ; 17 (2) : 132-144. https://doi.org/10.5230/jgc.2017.17.e16.
  • Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer : Current options and future directions. World J Gastroenterol. 2015 ; 21 (41) : 11621-11635. https://doi.org/10.3748/wjg.v21.i41.11621.
  • Cotes Sanchís A, Gallego J, Hernandez R, et al. Second-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry. PLoS One. 2020 ; 15 (7) : e0235848. Published 2020 Jul 31. https://doi.org/10.1371/journal.pone.0235848.
  • Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 ; 47 (15) : 2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002.
  • Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 ; 15 (1) : 78-86. https://doi.org/10.1016/S1470-2045(13)70549-7.
  • Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone [published correction appears in J Clin Oncol. 2012 Aug 20 ; 30 (24) : 3035]. J Clin Oncol. 2012 ; 30 (13) : 1513- 1518. https://doi.org/10.1200/JCO.2011.39.4585.
  • Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial. J Clin Oncol. 2013 ; 31 (35) : 4438-4444. https://doi.org/10.1200/JCO.2012.48.5805.
  • Casak SJ, Fashoyin-Aje I, Lemery SJ, et al. FDA Approval Summary : Ramucirumab for Gastric Cancer. Clin Cancer Res. 2015 ; 21 (15) : 3372-3376. https://doi.org/10.1158/1078-0432.CCR-15-0600.
  • Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 ; 383 (9911) : 31-39. https://doi.org/10.1016/S01406736(13)61719-5.
  • Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) : a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 (11) : 1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6.
  • Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia) : a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 ; 6 (12) : 1015-1024. https://doi.org/10.1016/S24681253(21)00313-7.
  • Di Bartolomeo M, Niger M, Tirino G, et al. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer : Real-World Data from the RAMoss Study. Target Oncol. 2018 ; 13 (2) : 227- 234. https://doi.org/10.1007/s11523-018-0562-5.
  • Paulson AS, Hess LM, Liepa AM, et al. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer. 2018 ; 21 (5) : 831-844. https://doi.org/10.1007/s10120-018-0796-z.
  • Jung M, Ryu MH, Oh DY, et al. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018 ; 21 (5) : 819-830. https://doi.org/10.1007/s10120-018-0806-1.
  • Lorenzen S, Thuss-Patience P, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022 ; 165 : 48-57. https://doi.org/10.1016/j.ejca.2022.01.015.
  • Park H, Sanjeevaiah A, Hosein P, et al., Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma : Final analysis of a phase II trial. 10.1200/JCO.2022.40.4_suppl. 284.
  • Tryakin A, Perminova E, Stroyakovsky D, et al. Ramucirumab in the treatment of refractory metastatic gastric cancer : Results from the RamSelGa trial. Ann. Oncol. 30, v306-v307 (2019). https://doi.org/https://doi.org/10.1093/annonc/mdz247.123.
  • Shitara K, https://doi.org/T, Dvorkin M, et al. Trifluridine / tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2018 Dec ; 19 (12) : e668]. Lancet Oncol. 2018 ; 19 (11) : 1437-1448. https://doi.org/10.1016/S1470-2045(18)30739-3.
  • Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE) : A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol. 2016 ; 34 (23) : 2728-2735. https://doi.org/10.1200/JCO.2015.65.1901.
  • Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer : WJOG7112G (T-ACT Study). J Clin Oncol. 2020 ; 38 (17) : 1919-1927. https://doi.org/10.1200/JCO.19.03077.
  • Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations : TyTAN--a randomized, phase III study. J Clin Oncol. 2014 ; 32 (19) : 2039- 2049. https://doi.org/10.1200/JCO.2013.53.6136.
  • Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY) : an international randomised, open-label, adaptive, phase 2 / 3 study. Lancet Oncol. 2017 ; 18 (5) : 640-653. https://doi.org/10.1016/S1470-2045(17)30111-0.
  • Rha S, Kim C, Jung M, et al, Multicenter phase Ib / II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer : Updated HER-RAM study with biomarker analysis, 10.1200/JCO.2022.40.4_suppl.330.
  • Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 ; 382 (25) : 2419-2430. https://doi.org/10.1056/NEJMoa2004413.
  • Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 ; 390 (10111) : 2461-2471. https://doi.org/10.1016/S01406736(17)31827-5.
  • Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study : Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer [published correction appears in J Clin Oncol. 2019 Feb 10 ; 37 (5) : 443]. J Clin Oncol. 2018 ; 36 (28) : 2836-2844. https://doi.org/10.1200/JCO.2017.76.6212.
  • Fuchs CS, https://doi.org/T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer : Phase 2 Clinical KEYNOTE-059 Trial [published correction appears in JAMA Oncol. 2019 Apr 1 ; 5 (4) : 579]. JAMA Oncol. 2018 ; 4 (5) : e180013. https://doi.org/10.1001/jamaoncol.2018.0013.
  • Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 ; 392 (10142) : 123-133. https://doi.org/10.1016/S01406736(18)31257-1.
  • Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer : The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 ; 6 (10) : 1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370.
  • Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4) : a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 ; 23 (2) : 234-247. https://doi.org/10.1016/S1470-2045(21)00692-6.
  • Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649) : a randomised, open-label, phase 3 trial. Lancet. 2021 ; 398 (10294) : 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2.
  • Shitara, K, Janjigian, Y, Moehler, M, et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer / gastroesophageal junction cancer / esophageal adenocarcinoma (GC / GEJC / EAC) : Expanded efficacy, safety, and subgroup analyses from CheckMate 649. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 240-240. https://doi.org/0.1200/JCO.2022.40.4_suppl.240.
  • Shitara, K., Ajani, J. A., Moehler, M. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942-948 (2022). https://doi.org/10.1038/s41586022-04508-4.
  • Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 ; 600 (7890) : 727-730. https://doi.org/10.1038/s41586-021-04161-3.
  • Yeong J, Lum HYJ, Teo CB, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022 ; 25 (4) : 741-750. https://doi.org/10.1007/s10120-022-01301-0.
  • Zhou KI, Peterson B, Serritella A, et al. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clin Cancer Res. 2020 ; 26 (24) : 6453-6463. https://doi.org/10.1158/1078-0432.CCR-20-2085.
  • Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021 ; 7 (6) : 895-902. https://doi.org/10.1001/jamaoncol.2021.0275.
  • Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability / Mismatch Repair-Deficient Cancer : Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 ; 38 (1) : 1-10. https://doi.org/: 10.1200/JCO.19.02105.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp